Key facts
- This page summarizes Robert E. George's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 22 Jun 2022, 19:03.
Robert E. George - 20 Jun 2022 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)
- Role
- Director
- Signature
- /s/ Jonathan Foster by Power of Attorney
- Issuer symbol
- MBRX
- Transactions as of
- 20 Jun 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 22 Jun 2022, 19:03:42 UTC
- Previous filing
- 09 Jun 2021
- Next filing
- 26 May 2023
- SEC
- View on sec.gov
Key filing fact
Robert E. George filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 22 Jun 2022.
Change
- Previous filing in this sequence was filed on 09 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
MBRX
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +23,333
- Change %
- +87%
- Price
- Shares after
- 50,001
- Date
- 20 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,333
- Exercise price
- $1.49
- Footnotes
- F1, F3
MBRX
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +15,000
- Change %
- +30%
- Price
- Shares after
- 65,001
- Date
- 20 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $1.49
- Footnotes
- F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. |
| F2 | The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date. |
| F3 | The options were issued in connection with the reporting person's Board of Director service to the Company. |